391 related articles for article (PubMed ID: 31524533)
1. Multi-drug approaches to NASH: what's in the development pipeline?
Johnston MP; Patel J; Byrne CD
Expert Opin Investig Drugs; 2020 Feb; 29(2):143-150. PubMed ID: 31524533
[No Abstract] [Full Text] [Related]
2. Promising therapies for treatment of nonalcoholic steatohepatitis.
Noureddin M; Zhang A; Loomba R
Expert Opin Emerg Drugs; 2016 Sep; 21(3):343-57. PubMed ID: 27501374
[TBL] [Abstract][Full Text] [Related]
3. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
[TBL] [Abstract][Full Text] [Related]
4. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
Cusi K
Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological management of nonalcoholic fatty liver disease.
Barb D; Portillo-Sanchez P; Cusi K
Metabolism; 2016 Aug; 65(8):1183-95. PubMed ID: 27301803
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes.
Cernea S; Cahn A; Raz I
Expert Rev Clin Pharmacol; 2017 May; 10(5):535-547. PubMed ID: 28276774
[TBL] [Abstract][Full Text] [Related]
7. NASH (nonalcoholic steatohepatitis), diabetes, and macrovascular disease: multiple chronic conditions and a potential treatment at the metabolic root.
Colca J
Expert Opin Investig Drugs; 2020 Feb; 29(2):191-196. PubMed ID: 31928475
[No Abstract] [Full Text] [Related]
8. New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis.
Pydyn N; Miękus K; Jura J; Kotlinowski J
Pharmacol Rep; 2020 Feb; 72(1):1-12. PubMed ID: 32016853
[TBL] [Abstract][Full Text] [Related]
9. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
10. Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis.
Verzijl CRC; Van De Peppel IP; Struik D; Jonker JW
Expert Opin Investig Drugs; 2020 Feb; 29(2):125-133. PubMed ID: 31899984
[No Abstract] [Full Text] [Related]
11. Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030.
Alswat K; Aljumah AA; Sanai FM; Abaalkhail F; Alghamdi M; Al Hamoudi WK; Al Khathlan A; Al Quraishi H; Al Rifai A; Al Zaabi M; Babatin MA; Estes C; Hashim A; Razavi H
Saudi J Gastroenterol; 2018; 24(4):211-219. PubMed ID: 29956688
[TBL] [Abstract][Full Text] [Related]
12. Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): prevalence, therapeutic innovations, and stumbling blocks for clinical development.
Alkhouri N
Expert Opin Investig Drugs; 2020 Feb; 29(2):115-116. PubMed ID: 31971024
[No Abstract] [Full Text] [Related]
13. Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH).
Westerouen Van Meeteren MJ; Drenth JPH; Tjwa ETTL
Expert Opin Investig Drugs; 2020 Feb; 29(2):117-123. PubMed ID: 31523999
[No Abstract] [Full Text] [Related]
14. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease.
Brown E; Hydes T; Hamid A; Cuthbertson DJ
Clin Ther; 2021 Sep; 43(9):1476-1504. PubMed ID: 34446271
[TBL] [Abstract][Full Text] [Related]
15. Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?
Paschos P; Athyros VG; Tsimperidis A; Katsoula A; Grammatikos N; Giouleme O
Curr Vasc Pharmacol; 2018; 16(3):269-275. PubMed ID: 28676018
[TBL] [Abstract][Full Text] [Related]
16. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors.
Muzurović E; Peng CC; Belanger MJ; Sanoudou D; Mikhailidis DP; Mantzoros CS
Hypertension; 2022 Jul; 79(7):1319-1326. PubMed ID: 35465684
[TBL] [Abstract][Full Text] [Related]
17. Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis.
Finck BN
Diabetes; 2018 Dec; 67(12):2485-2493. PubMed ID: 30459251
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
[TBL] [Abstract][Full Text] [Related]
19. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
Estes C; Anstee QM; Arias-Loste MT; Bantel H; Bellentani S; Caballeria J; Colombo M; Craxi A; Crespo J; Day CP; Eguchi Y; Geier A; Kondili LA; Kroy DC; Lazarus JV; Loomba R; Manns MP; Marchesini G; Nakajima A; Negro F; Petta S; Ratziu V; Romero-Gomez M; Sanyal A; Schattenberg JM; Tacke F; Tanaka J; Trautwein C; Wei L; Zeuzem S; Razavi H
J Hepatol; 2018 Oct; 69(4):896-904. PubMed ID: 29886156
[TBL] [Abstract][Full Text] [Related]
20. [New aspects of nonalcoholic steatohepatitis].
Stefan N
Internist (Berl); 2019 Feb; 60(2):128-132. PubMed ID: 30645665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
